Nasdaq · Healthcare

Atara Biotherapeutics, Inc. (ATRA)

As-reported financials and recent SEC filings for Atara Biotherapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$120.8M

Net income

$32.7M

Net margin

27.1%

Diluted EPS

$2.57

ROE

-84.9%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$120.8M	$128.9M	$8.6M	$63.6M	—
Gross profit	—	—	—	—	—
Operating income	$35.9M	$-83.4M	$-276.0M	$-280.5M	$-340.5M
Net income	$32.7M	$-85.4M	$-276.1M	$-228.3M	$-340.1M
Diluted EPS	$2.57	$-11.41	$-65.19	$-53.76	$-87.12

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

32026-07-06

8-K2026-06-26

42026-06-15

32026-06-15

S-82026-06-12

8-K2026-06-12

42026-06-11

42026-06-11

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ATRA

Search Atara Biotherapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.